By Fineline Cube 
Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary of New Frontier Group, for sacituzumab tirumotecan (sac‑TMT, also known as SKB264/MK‑2870; trade name: Sac‑TMT/Jia Tai Lai) across Hong Kong SAR and Macao SAR, China. The agreement extends the commercial footprint of the company’s flagship TROP2 antibody‑drug conjugate (ADC) beyond Mainland China.
Deal Overview
| Item | Detail |
|---|---|
| Licensor | Kelun-Biotech (HKG: 6990) |
| Partner | New Frontier Health Technology (subsidiary of New Frontier Group) |
| Product | Sacituzumab tirumotecan (sac‑TMT / SKB264 / MK‑2870; trade name Sac‑TMT / Jia Tai Lai) |
| Drug Class | Antibody‑drug conjugate (ADC) |
| Target | Human trophoblast cell surface antigen 2 (TROP2) |
| Territory | Hong Kong SAR and Macao SAR, China |
| Deal Type | Strategic commercialization agreement |
| Announcement Date | 10 Aug 2026 |
Product Profile
- Molecule: Sacituzumab tirumotecan, an ADC independently developed by Kelun‑Biotech
- Target: TROP2 (human trophoblast cell surface antigen 2)
- Approval Status: Currently holds 4 approved indications in Mainland China
- Asset Codes: Known as SKB264 (Kelun‑Biotech) and MK‑2870 (MSD), reflecting the asset’s dual development identity under the global partnership
Global Partnership Structure
| Region | Rights Holder |
|---|---|
| Outside Greater China | MSD (NYSE: MRK) — exclusive rights to develop, use, manufacture, and commercialize (licensed May 2022) |
| Greater China (Mainland China, Hong Kong, Macao, Taiwan) | Kelun‑Biotech |
In May 2022, Kelun‑Biotech granted MSD (NYSE: MRK) exclusive rights to develop, use, manufacture, and commercialize sacituzumab tirumotecan in all regions outside of Greater China. The new agreement with New Frontier Health Technology covers territories within Greater China where Kelun‑Biotech retains full rights, complementing — rather than overlapping with — the MSD alliance.
Market Impact & Outlook
- Commercial Expansion: The deal marks sacituzumab tirumotecan’s first dedicated commercialization arrangement for Hong Kong and Macao, extending a product already generating approvals in four Mainland China indications.
- ADC Momentum: TROP2‑directed ADCs remain one of the most active segments of oncology dealmaking, and Kelun‑Biotech’s asset — with its MSD‑backed global program — is among the most closely watched in the class.
- Channel Strategy: Partnering with New Frontier Health Technology, a healthcare services and distribution player, suggests a commercial model leveraging established regional channels rather than building an in‑field force in the two SARs.
- Rights Architecture: The structure keeps Greater China economics under Kelun‑Biotech control while MSD monetizes ex‑Greater China markets — a clean division that maximizes value capture on both sides.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization of sacituzumab tirumotecan in Hong Kong SAR and Macao SAR. Actual results may differ due to risks including regulatory developments, market adoption, and competitive dynamics.-Fineline Info & Tech